New Zealand markets closed

Serina Therapeutics, Inc. (SER)

NYSE American - NYSE American Delayed price. Currency in USD
Add to watchlist
8.14-0.66 (-7.50%)
At close: 04:00PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 20.36M
Enterprise value 19.83M
Trailing P/E 17.05
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)N/A
Enterprise value/revenue N/A
Enterprise value/EBITDA N/A

Trading information

Stock price history

Beta (5Y monthly) N/A
52-week change 3-59.66%
S&P500 52-week change 326.27%
52-week high 335.71
52-week low 38.10
50-day moving average 311.87
200-day moving average 317.91

Share statistics

Avg vol (3-month) 35.39k
Avg vol (10-day) 32.56k
Shares outstanding 52.5M
Implied shares outstanding 62.5M
Float 8890.08k
% held by insiders 156.07%
% held by institutions 11.57%
Shares short (30 Apr 2024) 45.47k
Short ratio (30 Apr 2024) 41.75
Short % of float (30 Apr 2024) 4N/A
Short % of shares outstanding (30 Apr 2024) 40.17%
Shares short (prior month 28 Mar 2024) 44.32k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 3N/A
Trailing annual dividend yield 3N/A
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 228:1000
Last split date 315 Mar 2024

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin 167.11%
Operating margin (ttm)7.81%

Management effectiveness

Return on assets (ttm)-39.79%
Return on equity (ttm)594.21%

Income statement

Revenue (ttm)3.15M
Revenue per share (ttm)1.38
Quarterly revenue growth (yoy)5,258.50%
Gross profit (ttm)N/A
EBITDA -3.04M
Net income avi to common (ttm)5.27M
Diluted EPS (ttm)N/A
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)7.62M
Total cash per share (mrq)3.09
Total debt (mrq)3.69M
Total debt/equity (mrq)89.88%
Current ratio (mrq)5.39
Book value per share (mrq)N/A

Cash flow statement

Operating cash flow (ttm)-2.48M
Levered free cash flow (ttm)-1.82M